News

“This is the most advanced stage of testing a human Rift Valley fever vaccine has ever reached in an outbreak-prone area,” said Peter Hart, CEPI’s Rift Valley fever Programme Lead.  “Of course, CEPI's priority for RVF is developing a safe and effective human vaccine, but the fact this vaccine may be able to protect both humans and animals—in other words it could be a so-called “dual use” vaccine—is an important step in a One Health approach to RVF prevention and control.”   

SEE: A plan to protect lives and livelihoods from a mosquito-borne killer | CEPI

https://cepi.net/innovations-for-impact/plan-protect-lives-and-livelihoods-mosquito-borne-killer